Skip to main content

Table 3 Clinical characteristics of NPC patients in the training, retrospective validation, and prospective validation cohorts

From: A new prognostic histopathologic classification of nasopharyngeal carcinoma

Characteristic

Training cohort

Retrospective validation cohort

Prospective validation cohort

Total (cases)

2716

1702

1613

Age (years)

 Median (range)

46 (10–86)

47 (10–90)

47 (11–83)

Follow-up time (months)

 Median (range)

68 (1–120)

68 (1–120)

41 (1–91)

Sex [cases (%)]

 Female

658 (24.2)

501 (29.4)

404 (25.1)

 Male

2058 (75.8)

1201 (70.6)

1209 (74.9)

Clinical stage [cases (%)]

 I

75 (2.8)

67 (4.0)

35 (2.2)

 II

549 (20.2)

388 (22.8)

104 (6.5)

 III

1272 (46.8)

695 (40.8)

458 (28.4)

 IV

820 (30.2)

552 (32.4)

1016 (62.9)

Therapeutic modality [cases (%)]

 Radiotherapy alone

1592 (58.6)

928 (54.5)

220 (13.6)

 Radiochemotherapy

1124 (41.4)

774 (45.5)

1393 (86.4)

Proposed classification [cases (%)]

 EC

1520 (55.9)

987 (58.0)

1202 (74.5)

 MSEC

598 (22.0)

420 (24.7)

229 (14.2)

 SC

489 (18.0)

198 (11.6)

135 (8.4)

 SCC

109 (4.1)

97 (5.7)

47 (2.9)

WHO classification [case (%)]

 NKUC

2261 (83.2)

1425 (83.8)

1185 (73.5)

 NKDC

409 (15.1)

227 (13.3)

414 (25.7)

 KSCC

46 (1.7)

50 (2.9)

14 (0.8)

OS rate (%)

 5-year (95% CI)

68.7 (66.9–70.5)

73.3 (71.1–75.4)

83.5 (81.1–85.6)

  1. NPC nasopharyngeal carcinoma, EC epithelial carcinoma, SC sarcomatoid carcinoma, MSEC mixed sarcomatoid-epithelial carcinoma, SCC squamous cell carcinoma, WHO World Health Organization, NKUC non-keratinizing undifferentiated carcinoma, NKDC non-keratinizing differentiated carcinoma, KSCC keratinizing squamous cell carcinoma, OS overall survival, CI confidence interval